Vivos' cost-cutting initiatives also led to a $1 million or 27% year-over-year reduction in operating loss, versus the third quarter of 2023. For the nine months ended September 30, 2024 operating ...
Vivos Therapeutics, Inc. ( NASDAQ: VVOS) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Kirk Huntsman - Chariman & CEO Brad Amman - CFO Scott Henry - Alliance Global Partners Lucas Ward ...
A doctor discusses the beauty breathing technique that could be the solution to snoring and other breathing abnormalities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback